Cardio Diagnostics Holdings Inc. CDIO shares are trading higher Tuesday after the company announced its AI-driven molecular heart disease test has received an Innovation Technology contract from Vizient, Inc.
The Details:
Cardio Diagnostics announced its AI-driven molecular heart disease test has received an Innovation Technology contract from Vizient, which services a customer base encompassing over 60% of hospitals and 97% of academic medical centers in the United States.
"We are honored to receive this contract from Vizient, which will accelerate access to our novel heart disease tests that leverage AI and a precision medicine approach," said Cardio Diagnostics CEO, Meesha Dogan, PhD.
"This contract recognizes our mission to transform cardiovascular disease management through advanced diagnostics. Our team is excited to make cardiovascular care more accessible across the country through this contract."
Shares of CDIO are up on heavy trading volume following the announcement. According to data from Benzinga Pro, more than 103 million shares have already been traded in the session, compared to the stock's 100-day average of less than 704 thousand shares.
Related News: What's Going On With Spirit Airlines Stock?
CDIO Price Action: According to Benzinga Pro, shares are over 52% at 32 cents at the time of publication.
Image: Merlin Lightpainting from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
